Cell Source, Inc. announced that Dr. Hermann Einsele, Professor of Internal Medicine and Director of the Department of Internal Medicine of the Julius Maximilian University, WA1/4rzburg, Germany, has joined its Scientific Advisory Board. Dr. Einsele is the Chairman of the German Study Group on Multiple Myeloma and serves on the Board of Directors of both the German Society of Blood and Marrow Stem Cell Transplantation and the German Lymphoma Group. He is part of the working group for Infectious Disease, Chronic Leukemia and Immunobiology at the European Group for Blood and Marrow Transplantation (EBMT).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +300.00% | 0.00% | -99.83% |
03-22 | Cell Source, Inc. announced that it has received $4.76017 million in funding | CI |
2023 | Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-99.83% | 32.82K | |
+9.85% | 115B | |
+11.79% | 106B | |
-2.59% | 21.96B | |
-13.49% | 21.87B | |
-5.29% | 19.21B | |
-2.85% | 18.08B | |
-38.57% | 17.71B | |
+6.29% | 14.32B | |
+33.78% | 12.42B |
- Stock Market
- Equities
- CLCS Stock
- News Cell Source, Inc.
- Cell Source, Inc. Announces Hermann Einsele Joins its Scientific Advisory Board